Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 07/29 05:35:19 pm
5048 GBp   +0.42%
07/29 ASTRAZENECA : *lbbw raises astrazeneca price target to 4800 pence - ..
07/29 ASTRAZENECA : Astra shares fly after cholesterol damage results
07/29 ASTRAZENECA : *bernstein raises astrazeneca price target to 5168 pen..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

AstraZeneca CEO Leaving As Profits Slide, Warns On Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 08:56am CEST

AstraZeneca PLC (AZN) Thursday said Chief Executive David Brennan is leaving after the troubled drug maker missed its first-quarter earnings and sales forecasts and cut its full-year profit targets yet again.

AstraZeneca, which reports in dollars, said net profit in the first three months of 2012 fell 44% to $1.64 billion from $2.91 billion a year earlier, missing analysts' expectations of $2.0 billion. Revenue was down 11% at $7.35 billion, compared with $8.29 billion a year earlier, worse than the $7.98 billion expected in a survey of 10 analysts.

Brennan, who used the update to announce his retirement, said, "The anticipated impact from the loss of exclusivity on several brands, together with challenging market conditions, has made for a difficult start to the year in revenue terms.

"Delivery on our restructuring plans and continued discipline on operating costs, together with the benefits from a lower tax rate, will only partially mitigate the revenue pressures. As a result we have lowered our core EPS [earnings per share] target for the full year to the range of $5.85 to $6.15."

The company previously foresaw core EPS coming in this year at $6.00 to $6.30, after $7.28 in 2011.

Brennan, an American, has been CEO since the start of 2006. Chief Financial Officer Simon Lowth will act as interim chief executive from June until a permanent successor is in place.

AstraZeneca faces crucial patent expiries between now and 2015 on products such as antipsychotic Seroquel and ulcer medicine Nexium, and the loss of patent protection in the U.S. in 2016 for its best-selling drug, heart drug Crestor. Coupled with a thinner late-stage pipeline and a mixed longer-term research and development track record, the U.K.'s No. 2 drug maker by sales has taken an aggressive approach to costs, shrinking operations and cutting thousands of jobs, while keeping cash flowing to shareholders.

In February, AstraZeneca announced it was cutting around 7,300 jobs as part of the company's ongoing cost-savings program. The first phase, launched in 2007, was aimed at improving long-term competitiveness and productivity. The second phase, announced in January 2010, envisioned the loss of up to 10,400 jobs by 2014.

Describing its outlook for 2012, the company said in a statement that "we now expect the decline in revenue for the full year will be in the range of the low to mid-teens in constant-currency terms."

AstraZeneca, which spent $5.6 billion last year buying back its own shares, Thursday said it spent $912 million in the first quarter on net stock repurchases.

AstraZeneca shares ended Wednesday at 2841 pence, down 6% on year-earlier levels.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
07/29 ASTRAZENECA : *lbbw raises astrazeneca price target to 4800 pence - 'hold'
07/29 ASTRAZENECA : Astra shares fly after cholesterol damage results
07/29 ASTRAZENECA : *bernstein raises astrazeneca price target to 5168 pence - 'market..
07/28 ASTRAZENECA : beats 2Q profit forecasts
07/28DJASTRAZENECA : Posts $3 Million Loss
07/28DJASTRAZENECA : Posts $3 Million Loss -- Update
07/28 ASTRAZENECA : says 2Q earnings fell 22 per cent
07/28 ASTRAZENECA : says 2Q earnings fell 22 percent
07/28 AZN : H1 2016 Results
07/28DJASTRAZENECA : Posts 2Q Loss as Cholesterol Drug Crestor Loses Exclusivity
More news
Sector news : Pharmaceuticals - NEC
08:48aDJMERCK : Earnings Watch -- WSJ
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/29 After Hours Gainers / Losers
07/29 AstraZeneca Solid And Safe, With Upside From Biologic Pipeline
07/28 AstraZeneca up 6% on rumored Novartis interest
07/28 AstraZeneca Q2 top line down 11%; net income off 105%; cash flow down 83%; sh..
07/28 WALL STREET BREAKFAST : Crude Nears Fresh Bear Market
Advertisement
Financials ($)
Sales 2016 23 013 M
EBIT 2016 5 575 M
Net income 2016 2 692 M
Debt 2016 11 262 M
Yield 2016 4,17%
P/E ratio 2016 33,16
P/E ratio 2017 29,96
EV / Sales 2016 4,14x
EV / Sales 2017 4,19x
Capitalization 84 029 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 68,7 $
Spread / Average Target 2,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Edward Bradley Senior VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC9.35%84 029
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
NOVARTIS AG-5.30%215 109
MERCK & CO., INC.11.06%162 372
More Results